middle.news

Argenica Seeks FDA Meeting After New Pathway Emerges for Xaranetide

4:44pm on Thursday 19th of November, 2026 AEDT • Biotechnology
Read Story

Argenica Seeks FDA Meeting After New Pathway Emerges for Xaranetide

4:44pm on Thursday 19th of November, 2026 AEDT
Key Points
  • FDA maintains clinical hold on xaranetide IND
  • GLP rat study required to assess potential Olney lesions
  • Permitted exposure limit set below proposed Phase 2b doses
  • Argenica preparing a Type A FDA meeting
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Argenica Therapeutics (ASX:AGN)
OPEN ARTICLE